Suivre
Steven ABRAMS
Steven ABRAMS
Professor, Global Health Institute, University of Antwerp & Data Science Institute, UHasselt
Adresse e-mail validée de uhasselt.be
Titre
Citée par
Citée par
Année
Time between symptom onset, hospitalisation and recovery or death: statistical analysis of Belgian COVID-19 patients
C Faes, S Abrams, D Van Beckhoven, G Meyfroidt, E Vlieghe, N Hens, ...
International journal of environmental research and public health 17 (20), 7560, 2020
164*2020
Seroprevalence of IgG antibodies against SARS-CoV-2–a serial prospective cross-sectional nationwide study of residual samples, Belgium, March to October 2020
SA Herzog, J De Bie, S Abrams, I Wouters, E Ekinci, L Patteet, A Coppens, ...
Eurosurveillance 27 (9), 2100419, 2022
87*2022
Modelling the early phase of the Belgian COVID-19 epidemic using a stochastic compartmental model and studying its implied future trajectories
S Abrams, J Wambua, E Santermans, L Willem, E Kuylen, P Coletti, ...
Epidemics 35, 100449, 2021
55*2021
The impact of contact tracing and household bubbles on deconfinement strategies for COVID-19
L Willem, S Abrams, PJK Libin, P Coletti, E Kuylen, O Petrof, ...
Nature communications 12 (1), 1-9, 2021
48*2021
Resurgence risk for measles, mumps and rubella in France in 2018 and 2020
G Béraud, S Abrams, P Beutels, B Dervaux, N Hens
Eurosurveillance 23 (25), 1700796, 2018
402018
COVID-19 mortality, excess mortality, deaths per million and infection fatality ratio, Belgium, 9 March 2020 to 28 June 2020
G Molenberghs, C Faes, J Verbeeck, P Deboosere, S Abrams, L Willem, ...
Eurosurveillance 27 (7), 2002060, 2022
36*2022
Assessing the risk of measles resurgence in a highly vaccinated population: Belgium anno 2013
N Hens, S Abrams, E Santermans, H Theeten, N Goeyvaerts, T Lernout, ...
Eurosurveillance 20 (1), 20998, 2015
302015
A data-driven metapopulation model for the Belgian COVID-19 epidemic: assessing the impact of lockdown and exit strategies
P Coletti, P Libin, O Petrof, L Willem, S Abrams, SA Herzog, C Faes, ...
BMC infectious diseases 21 (1), 1-12, 2021
24*2021
Assessing mumps outbreak risk in highly vaccinated populations using spatial seroprevalence data
S Abrams, P Beutels, N Hens
American journal of epidemiology 179 (8), 1006-1017, 2014
232014
Immunogenicity and persistence of trivalent measles, mumps, and rubella vaccines: a systematic review and meta-analysis
J Schenk, S Abrams, H Theeten, P Van Damme, P Beutels, N Hens
The Lancet Infectious Diseases 21 (2), 286-295, 2021
222021
Donor‐derived cell‐free DNA as a biomarker for rejection after kidney transplantation: a systematic review and meta‐analysis
VPWM Wijtvliet, P Plaeke, S Abrams, N Hens, EM Gielis, R Hellemans, ...
Transplant International 33 (12), 1626-1642, 2020
192020
Comparison of Diagnostic Tests for Onchocerca volvulus in the Democratic Republic of Congo
A Hotterbeekx, J Perneel, M Mandro, G Abhafule, JN Siewe Fodjo, ...
Pathogens 9 (6), 435, 2020
122020
Single versus multiple dose ivermectin regimen in onchocerciasis-infected persons with epilepsy treated with phenobarbital: a randomized clinical trial in the Democratic …
M Mandro, JN Siewe Fodjo, A Dusabimana, D Mukendi, S Haesendonckx, ...
Pathogens 9 (3), 205, 2020
122020
Modeling individual heterogeneity in the acquisition of recurrent infections: an application to parvovirus B19
S Abrams, N Hens
Biostatistics 16 (1), 129-142, 2015
112015
Inferring rubella outbreak risk from seroprevalence data in Belgium
S Abrams, E Kourkouni, M Sabbe, P Beutels, N Hens
Vaccine 34 (50), 6187-6192, 2016
102016
Infectious diseases epidemiology, quantitative methodology, and clinical research in the midst of the COVID-19 pandemic: Perspective from a European country
G Molenberghs, M Buyse, S Abrams, N Hens, P Beutels, C Faes, ...
Contemporary clinical trials 99, 106189, 2020
82020
Ivermectin treatment response in onchocerca volvulus infected persons with epilepsy: A three-country short cohort study
A Dusabimana, D Bhwana, S Raimon, BP Mmbando, A Hotterbeekx, ...
Pathogens 9 (8), 617, 2020
82020
mRNA-1273 vaccine (Moderna): a better option than BNT162b2 (Pfizer) in kidney transplant recipients and dialysis patients?
VPWM Wijtvliet, KK Ariën, S Abrams, MM Couttenye, F Mestrez, J Mariën, ...
Nephrology Dialysis Transplantation 37 (4), 799-803, 2022
62022
Sample size calculation for estimating key epidemiological parameters using serological data and mathematical modelling
S Blaizot, SA Herzog, S Abrams, H Theeten, A Litzroth, N Hens
BMC medical research methodology 19 (1), 1-12, 2019
62019
Measuring association among censored antibody titer data
TMP Tran, S Abrams, M Aerts, K Maertens, N Hens
Statistics in Medicine 40 (16), 3740-3761, 2021
52021
Le système ne peut pas réaliser cette opération maintenant. Veuillez réessayer plus tard.
Articles 1–20